Monte Rosa Therapeutics, Inc. (GLUE)
10.31
-0.01
(-0.10%)
USD |
NASDAQ |
Oct 09, 16:00
10.30
-0.01
(-0.10%)
After-Hours: 20:00
Monte Rosa Therapeutics Debt to Equity Ratio : 0.078 for June 30, 2026
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.078 |
| March 31, 2026 | 0.0748 |
| December 31, 2025 | 0.1682 |
| September 30, 2025 | 0.1634 |
| June 30, 2025 | 0.1534 |
| March 31, 2025 | 0.1521 |
| December 31, 2024 | 0.1916 |
| September 30, 2024 | 0.2127 |
| June 30, 2024 | 0.1974 |
| March 31, 2024 | 0.2962 |
| December 31, 2023 | 0.2568 |
| September 30, 2023 | 0.2514 |
| Date | Value |
|---|---|
| June 30, 2023 | 0.2201 |
| March 31, 2023 | 0.1894 |
| December 31, 2022 | 0.1732 |
| September 30, 2022 | 0.1569 |
| June 30, 2022 | 0.1614 |
| March 31, 2022 | 0.0214 |
| December 31, 2021 | 0.00 |
| September 30, 2021 | 0.00 |
| June 30, 2021 | 0.00 |
| March 31, 2021 | -3.814 |
| December 31, 2020 | -1.391 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| United Therapeutics Corp. | 0.00 |
| ACADIA Pharmaceuticals, Inc. | 0.0565 |
| Alnylam Pharmaceuticals, Inc. | 2.206 |
| Anika Therapeutics, Inc. | 0.1839 |
| Savara, Inc. | 0.2117 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 691.16M |
| Total Liabilities (Quarterly) | 203.88M |
| Shareholders Equity (Quarterly) | 487.28M |
| Current Ratio | 10.58 |
| Net Debt Paydown Yield | 0.04% |